Etanercept improves psoriatic arthritis patient-reported outcomes: Results from EDUCATE

Cutis

Volumn 79, Issue 4, 2007, Pages 322-326

  Frankel, Ellen H ^a   Strober, Bruce E ^b   Crowley, Jeffrey J ^c   Fivenson, David P ^d   Woolley, J Michael ^e   Yu, Elaine B ^e   Xia, Hong A ^e   Chiou, Chiun Fang ^e   Stevens, Seth R ^e  

^a Clinical Partners   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Private Practice   (United States)

^d Private Practice   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; HYBRID PROTEIN; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HEALTH STATUS; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ARTHRITIS, PSORIATIC; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 34248399606     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62;2447-2457.
2. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(suppl 2): ii14-17.
3. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-721. Epub 2006 Feb 1.
4. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50: 2264-2272.
5. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-390.
6. Clinical Study Results Web site. Synopsis: a multicenter, open-label study to observe the effect of etanercept on joint and skin disease in subjects with psoriatic arthritis. Available at: http://www.clinicalstudyresults.org/ documents/company-study_550_0.pdf. Accessed April 21, 2006.
7. Enbrel [package insert]. Thousand Oaks, Calif: Amgen Inc; 2006.
8. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dematol Symp Proc. 2004;9:169-180.
9. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of changes in Dermatology Life Quality Index scores [abstract]. Brit J Derm. 2002;147(suppl 62):50.
10. Krueger G. New method being developed for assessing psoriasis. NPF psoriasis score - your input needed. Psoriasis Foundation Psoriasis Forum. 1999;5:1-5.
11. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
12. Mease P, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis. 2004;63 (suppl 1):391.
13. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford).2003;42:1460-1468.
14. Harrison BJ, Silman AJ, Barrett EM, et al. Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol. 1997;24: 1744-1749.
15. Gottlieb AB, Mease PJ, Jackson JM, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat. 2006;17:279-287.